C. Dujon

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

R. Corre, Laurent Greillier, H. Le Caer et al. · Journal of Clinical Oncology · 2016 · 407 citations

Medicine, Geriatric Medicine, Oncology +17

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study

Nicolas Delanoy, Jean‐Marie Michot, Thibault Comont et al. · The Lancet Haematology · 2018 · 292 citations

Pharmacy, Hematology, Immunology +16

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)

C. Chouaïd, C. Dujon, Pascal Dô et al. · Lung Cancer · 2014 · 187 citations

Medicine, Oncology, Surgery +8

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

Camille Mehlman, Jacques Cadranel, G. Rousseau-Bussac et al. · Lung Cancer · 2019 · 87 citations · Full text

Medicine, Oncology, Pharmacology +16

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies

D. Debieuvre, Olivier Molinier, L. Falchero et al. · The Lancet Regional Health - Europe · 2022 · 76 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16